Octreotide as adjunctive therapy for catecholamine-secreting pheochromocytoma and paraganglioma
- 21 August 2026
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Abstract
Context: Catecholamine-secreting pheochromocytomas and paragangliomas (PPGLs) can be difficult to stabilize before surgery or during follow-up. Somatostatin-receptor expression provides a rationale for octreotide therapy, but clinical evidence is limited. Objective: To evaluate clinical, biochemical, hemodynamic, metabolic, and perioperative outcomes associated with octreotide treatment in catecholamine-secreting PPGLs. Methods: We retrospectively studied 27 consecutive patients with PPGLs treated with octreotide at 2 referral centers in Muscat, Oman, between January 2012 and March 2026. Primary outcomes were clinical, hemodynamic, and biochemical responses; secondary outcomes included glycemic, surgical, and follow-up outcomes. Results: Twenty-seven patients were included (70.4% female; mean age, 50.3 ± 22.2 years); 14 had paraganglioma and 13 pheochromocytoma. All received long-acting octreotide, and 10 also received short-acting octreotide. Median plasma norepinephrine decreased from 6723 to 1901 pmol/L (P < .0001). Epinephrine, dopamine, and chromogranin A also decreased significantly. The mean blood pressure decreased from 154.8/93.5 to 123.0/75.3 mmHg (n = 24; P = .0003 for systolic and P = .0006 for diastolic pressure), and mean HbA1c decreased from 8.6 ± 2.4% to 6.2 ± 0.8% among patients with diabetes (n = 11; P = .005). Seventeen patients underwent uneventful surgical resection. During a median follow-up of 3 years, only 1 non–PPGL-related death occurred. Conclusions: Octreotide treatment was associated with biochemical, hemodynamic, and metabolic improvement and may serve as a useful adjunct in selected patients, particularly as a bridge to surgery and during perioperative preparation.Keywords
This publication has 22 references indexed in Scilit:
- Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paragangliomaJournal of Neuroendocrinology, 2025
- Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: a single center retrospective observational studyEndocrine, 2024
- Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the ClinicianEndocrine Practice, 2023
- Approach to the Patient: Perioperative Management of the Patient with Pheochromocytoma or Sympathetic ParagangliomaThe Journal of Clinical Endocrinology & Metabolism, 2020
- Pheochromocytoma and ParagangliomaNew England Journal of Medicine, 2019
- Severe hemodynamic instability during elective surgery for a patient with a giant pheochromocytomaInternational Journal of Surgery Case Reports, 2019
- Perioperative Management of PheochromocytomaJournal of Cardiothoracic and Vascular Anesthesia, 2017
- Preoperative Management of the Pheochromocytoma PatientThe Journal of Clinical Endocrinology & Metabolism, 2007
- Effects of slow‐release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytomaClinical Endocrinology, 2002
- Short‐term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo‐controlled trialClinical Endocrinology, 1995